After D-mab: Next-Generation Osteoporosis Drugs Focus On Building Bone
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen's osteoporosis and bone-related cancer drug denosumab may be one of the most eagerly-anticipated approvals of the year - not least by Amgen itself, whose future growth depends almost entirely on an FDA nod. But in another sense this antibody marks an ending, not a beginning
You may also be interested in...
Regenerating Interest In Novel Drugs For Postmenopausal Osteoporosis
New bone-targeted agents for osteoporosis must clear significant obstacles to succeed in a highly generic market, but safety concerns with established agents like bisphosphonates and calcitonin offer a foothold. Phase III anabolic candidates from Amgen and Radius Health aim to build new bone, the holy grail of osteoporosis treatment, but R&D in new anti-resorptive mechanisms to halt bone breakdown also continues.
Xarelto Action Letter No Surprise; But Does FDA Want Data, REMS Or Both?
As anticipated, FDA answered Johnson & Johnson/Bayer's NDA for anticoagulant Xarelto (rivaroxaban) with a complete response letter May 28
Likely Sales Slump Puts (Still More) Heat On Amgen’s Denosumab To Win
Analyst questions whether the bone drug’s efficacy can beat Zometa’s by the necessary 15 percent.